Zoetis Undervalued by Over 60%, Investing.com AI Analysis Suggests

An analysis by Investing.com's AI-powered stock selection tool has identified animal health leader Zoetis Inc. (NYSE:ZTS) as significantly undervalued, suggesting a potential upside of over 61% while the company's stock trades near its 52-week lows.

Valuation and Market Performance

According to the report from Investing.com, Zoetis stock is trading near its 52-week low at $76.20, with a price-to-earnings ratio of approximately 12x. The platform's proprietary "Fair Value" model, which aggregates multiple institutional-grade valuation methods, estimates the stock's intrinsic value at $122.88, implying a 61.3% upside.

This view is reportedly echoed by the broader market, with the Wall Street consensus price target averaging $114.76, which represents a potential 50.6% increase from current levels. The analysis points to a disconnect between the company's recent stock performance and its underlying business strength.

Underlying Business Fundamentals

The case for undervaluation is supported by the company's recent financial performance and strong operational metrics, as highlighted in the report:

Ad

• International Growth: The company's international segment sales grew by approximately 17% in the first quarter of 2026.
• Core Business Expansion: Its livestock division posted organic growth of around 12% in the same period.
• Profitability Metrics: Zoetis maintains robust financials, including gross margins of approximately 72% and a return on assets of 18%.
• Shareholder Returns: The company currently offers a dividend yield of 2.8%.

Growth Catalysts and Outlook

Looking ahead, the analysis identifies several potential catalysts that could help bridge the gap between the stock's market price and its estimated fair value. Recent developments include fresh regulatory approvals for Lenivia, its next-generation pain treatment for dogs, in markets such as the United Kingdom.

Furthermore, Zoetis has a pipeline of more than 12 products that are advancing toward commercialization. These factors, combined with its strong global pricing power, are cited as key reasons why the market may re-evaluate the company's growth prospects.